Erratum: US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials (Clinical Infectious Diseases (2017) 65 (324-327) DOI: 10.1093/cid/cix313);US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials

Clinical Infectious Diseases

Volumn 65, Issue 2, 2017, Pages 324-327

  Adimora, Adaora A ^a,b   Cole, Stephen R ^b   Eron, Joseph J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

black women and HIV prevention; clinical trial designs; HIV and racial disparities.; HIV epidemiology and African Americans; HIV prevention

Indexed keywords

AFRICA; ARTICLE; BLACK PERSON; CLINICAL TRIAL (TOPIC); DRUG CONCENTRATION; EPIDEMIC; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; ADULT; AFRICAN AMERICAN; BLOOD; ETHNOLOGY; MEDICATION COMPLIANCE; METHODOLOGY; PRE-EXPOSURE PROPHYLAXIS; RACISM; SAMPLE SIZE; UNITED STATES;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE; TENOFOVIR;

ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; EMTRICITABINE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MEDICATION ADHERENCE; PRE-EXPOSURE PROPHYLAXIS; RACISM; RESEARCH DESIGN; SAMPLE SIZE; TENOFOVIR; UNITED STATES;

EID: 85023193329     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix1078     Document Type: Erratum

References (22)

1. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74
3. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99
4. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410
5. Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34
6. Molina JM, Capitant C, Spire B, et al; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373:2237-46
7. Baeten JM, Palanee-Phillips T, Brown ER, et al; MTN-020-ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med 2016; 375:2121-32
8. Centers for Disease Control and Prevention. HIV Surveillance Report, 2015. Atlanta, GA: Division of HIV/AIDS Prevention, National Center for HIV/ AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, US Department of Health and Human Services, 2016
9. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva, Switzerland: UNAIDS, 2013
10. Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis 2005; 191(suppl 1):S115-22
11. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502
12. Marrazzo JM, Ramjee G, Richardson BA, et al; VOICE Study Team. Tenofovirbased preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372:509-18
13. Hodder SL, Justman J, Hughes JP, et al; HIV Prevention Trials Network 064; Women's HIV SeroIncidence Study Team. HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med 2013; 158:10-8
14. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387:53-60
15. Walensky RP, Jacobsen MM, Bekker LG, et al. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at highrisk for HIV infection. J Infect Dis 2016; 213:1523-31
16. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis 2013; 208:224-34
17. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012; 9:e1001245
18. Van Damme L, Corneli A, Ahmed K, et al; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-22
19. Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 2012; 9:48-55
20. Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target populations: the ACTG 320 trial. Am J Epidemiol 2010; 172:107-15
21. Stuart EA, Cole SR, Bradshaw CP, Leaf PJ. The use of propensity scores to assess the generalizability of results from randomized trials. J R Stat Soc Ser A Stat Soc 2010; 174:369-86
22. Keiding N, Louis TA. Perils and potentials of self-selected entry to epidemiological studies and surveys. J R Stat Soc Ser A Stat Soc 2016; 179:319-76